HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Safety and efficacy of firebird drug-eluting stent combination tirofiban in patients with acute coronary syndrome].

AbstractOBJECTIVE:
To evaluate the safety and efficacy of Firebird drug-eluting stent (DES) combining Tirofiban and Cypher DES combining Tirofiban in patients with acute coronary syndrome (ACS).
METHODS:
323 ACS patients were divided into 2 general conditions-matched groups: Firebird group (n = 161) undergoing Firebird DES implantation and Tirofiban intravenous injection 10 microg x kg(-1) within 3 minutes followed by Tirofiban 0.15 microg x kg(-1) x min(-1) intravenous maintenance infusion with micro pump for 36 hours, and Cypher group (n = 162) undergoing Cypher DES implantation and Tirofiban. The safety was observed instantly and 36 h after the implantation. The patients were followed up for 30 d. Some patients in the Firebird group underwent coronary angiography and intravascular ultrasound because of angina and part of target vessels underwent revascularization.
RESULTS:
There were no significant differences between the 2 groups in ejection fraction target coronary lesion type, blood platelet count, HB and HCT before treatment. The success rates of operation were both 100% in these 2 groups. No complication occurred in both groups. There were not significant differences in the blood platelet count, hemoglobin, hematocrit, acute stent thrombosis rate (1.2% vs 1.2%), acute myocardial infarction rate (1.3% vs 1.3%), target vessel revascularization rate (0.6% vs 1.3%), and rehospitalization rate (1.3% vs 0.7%) (all P > 0.05). 30 d no in-stent restenosis was found by angiographic and intravascular ultrasound follow-up in the Firebird group.
CONCLUSION:
Firebird DES combining Tirofiban and Cypher DES combining Tirofiban are both safe and effective in treating ACS.
AuthorsYu-juan Zhao, Li-jun Zhou, Wei-min Li, Pi-dong Liu, Yan-dong Chen, Li-yun Song
JournalZhonghua yi xue za zhi (Zhonghua Yi Xue Za Zhi) Vol. 88 Issue 36 Pg. 2553-5 (Sep 23 2008) ISSN: 0376-2491 [Print] China
PMID19080649 (Publication Type: Controlled Clinical Trial, Journal Article)
Chemical References
  • Tyrosine
  • Tirofiban
Topics
  • Acute Coronary Syndrome (therapy)
  • Adult
  • Aged
  • Angioplasty, Balloon, Coronary
  • Drug-Eluting Stents (adverse effects)
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Tirofiban
  • Treatment Outcome
  • Tyrosine (adverse effects, analogs & derivatives, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: